ArticleBiomedicines2026

Anthracycline-Free Neoadjuvant Pertuzumab-Trastuzumab-Taxane in Patients with HER2-Positive Early Breast Cancer: Hormone Receptor Status as a Key Determinant of Pathological Complete Response.

Azzurra Irelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.